Article citationsMore>>
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y., Bas, T., Piperdi, B. and Halmos, B. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 15, 1657-1669.
https://doi.org/10.1016/j.jtho.2020.06.015
has been cited by the following article:
-
TITLE:
Pembrolizumab-Induced Steven-Johnson Syndrome in an NSCLC Patient: A Case Report
AUTHORS:
Shan Su, Xinxing Hu, Hongzhong Yang
KEYWORDS:
Pembrolizumab, Non-Small Cell Lung Cancer, Immune-Related Cutaneous Adverse Event, Steven-Johnson Syndrome
JOURNAL NAME:
Health,
Vol.14 No.1,
January
18,
2022
ABSTRACT: Background: Immune checkpoints inhibitors (ICIs) are widely used in various therapy of tumors. With the increasing usage of them, immune-related adverse events (irAEs) have been known and become common events, especially in the dermatologic system. However, the rare and severe immune-related cutaneous adverse events (irCAEs) still lack enough knowledge. Case presentation: We described a rare case of Steven-Johnson syndrome (SJS) induced by pembrolizumab in an advanced squamous non-small cell lung cancer (NSCLC) patient. SJS is a rare irCAE that could happen at any time after immunotherapy while this case happened from the 3rd day. The patient had influence-like symptoms and several mucous lesions including oral, eye, and skin. With a gradually severer condition, a stoss therapy of intravenous immunoglobulin (IVIG) had a mild effect. It was a long process and failed to respond to usual dermatologic treatment. Conclusion: We share this case in order to enhance clinicians’ ability to early recognition and diagnosis in severe irCAEs. Early recognition and appropriate management are important to evade the termination of immunotherapy. Such severe irCAE should be paid more attention to in clinical medicine when using ICIs.
Related Articles:
-
Anestakis Doxakis, Argyraki Maria, Petanidis Savvas, Iakovidou-Kritsi Zafiroula
-
Ebru Yilmaz, Cengiz Koç
-
Xinming Li
-
Pradeep Rasika Perera, Dinushka Wickramasinghe, Hemantha Peiris, Lal Chandrasena, Vajira Senaratne
-
Prosper Kouadio Kimou, François Emmanuel Tanoé, Kouassi Vincent Kouakou